Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? | Zendy

Johannes Merk | Zendy; Jana Rolff | Zendy; Cornelia Dorn | Zendy; Gunda Leschber | Zendy; Iduna Fichtner | Zendy

Open Access

Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?

Author(s) -

Johannes Merk,

Jana Rolff,

Cornelia Dorn,

Gunda Leschber,

Iduna Fichtner

Publication year - 2011

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1016/j.ejcts.2011.02.010

Subject(s) - abcg2 , carboplatin , lung cancer , etoposide , multiple drug resistance , cancer research , erlotinib , paclitaxel , gemcitabine , biology , chemotherapy , cancer , medicine , drug resistance , oncology , cisplatin , atp binding cassette transporter , epidermal growth factor receptor , biochemistry , microbiology and biotechnology , transporter , gene

In chemotherapy for non-small-cell lung cancer (NSCLC), some patients seem to exhibit an intrinsic resistance or develop an acquired resistance under treatment. Results on resistance markers for possible treatment failure as shown in studies on selected lung cancer cell lines could not be completely confirmed in clinical trials. As these conflicting data require further research, we created a model between cell culture and the clinical need to study this problem.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research